Physiologically‐based pharmacokinetic modeling‐guided dose Management of Oral Anticoagulants when initiating Nirmatrelvir/ritonavir (Paxlovid) for COVID‐19 …
Patients with coronavirus disease 2019 (COVID‐19) with cardiovascular diseases who are
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir …
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
SR Vazquez, AS Wilson, DM Witt - Journal of Thrombosis and …, 2022 - Springer
Nirmatrelvir-ritonavir (Paxlovid™) is a 5-day oral antiviral therapy given an Emergency Use
Authorization by the Food and Drug Administration in late 2021 for the outpatient treatment …
Authorization by the Food and Drug Administration in late 2021 for the outpatient treatment …
A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir/ritonavir
J Gerhart, DS Cox, RSP Singh, PLS Chan… - Clinical …, 2024 - Springer
Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …
Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir
J Gerhart, F Draica, M Benigno, J Atkinson… - The AAPS Journal, 2023 - Springer
Nirmatrelvir (coadministered with ritonavir as PAXLOVIDTM) reduces the risk of COVID-19-
related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 …
related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 …
Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income …
The COVID-19 pandemic sparked the development of novel anti-viral drugs that have shown
to be effective in reducing both fatality and hospitalization rates in patients with elevated risk …
to be effective in reducing both fatality and hospitalization rates in patients with elevated risk …
The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based …
MM Alsmadi - Drug Metabolism and Personalized Therapy, 2023 - degruyter.com
Objectives Therapy failure caused by complex population-drug-drug (PDDI) interactions
including CYP3A4 can be predicted using mechanistic physiologically-based …
including CYP3A4 can be predicted using mechanistic physiologically-based …
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
R Xu, W Ge, Q Jiang - European journal of clinical pharmacology, 2018 - Springer
Purpose Rivaroxaban is a direct oral anticoagulant with a large inter-individual variability.
The present study is to develop a physiologically based pharmacokinetic (PBPK) model to …
The present study is to develop a physiologically based pharmacokinetic (PBPK) model to …
Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications
C Marzolini, DR Kuritzkes, F Marra… - Clinical …, 2022 - Wiley Online Library
The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …
been granted authorization or approval in several countries for the treatment of patients with …
Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID‐19 trial of nirmatrelvir
RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - Wiley Online Library
Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF …
Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
PLS Chan, RSP Singh, DS Cox, H Shi… - CPT …, 2023 - Wiley Online Library
Protease inhibitor nirmatrelvir coadministered with ritonavir as a pharmacokinetic enhancer
(PAXLOVID™; Pfizer Inc) became the first orally bioavailable antiviral agent granted …
(PAXLOVID™; Pfizer Inc) became the first orally bioavailable antiviral agent granted …